0
We're unable to sign you in at this time. Please try again in a few minutes.
Retry
We were able to sign you in, but your subscription(s) could not be found. Please try again in a few minutes.
Retry
There may be a problem with your account. Please contact the AMA Service Center to resolve this issue.
Contact the AMA Service Center:
Telephone: 1 (800) 262-2350 or 1 (312) 670-7827  *   Email: subscriptions@jamanetwork.com
Error Message ......
Small Case Series |

Yellow Dye Laser Treatment of Vascularized Corneal Stromal Scars in Pediatric Patients FREE

Gregg T. Lueder, MD; Susan Culican, MD, PhD
[+] Author Affiliations

Section Editor: W. Richard Green, MD

More Author Information
Arch Ophthalmol. 2008;126(4):564-566. doi:10.1001/archopht.126.4.564.
Text Size: A A A
Published online

Patients with a variety of corneal diseases may develop stromal scars that interfere with vision. Vascularization of these scars may lead to inflammation, extravasation of lipid, and progressive opacification. Laser treatment of the neovascular vessels may induce regression of these vessels, with resultant increased corneal clarity and improved vision. We describe the treatment and outcome of 3 pediatric patients with vascularized corneal stromal scars treated with yellow dye laser. Using a PubMed search, we were unable to find any previous reports of this treatment in pediatric patients.

Informed consent was obtained from the patients and parents before performing the treatment. The affected eye was pretreated with pilocarpine hydrochloride, 2%. The laser was used with the patients awake using topical proparacaine hydrochloride. An iridotomy contact lens using high (×25) slitlamp magnification was used. A laser (Lumenis, Santa Clara, California) was used with a wavelength of 568 nm. The spot size was 50 μm. The power ranged from 200 to 300 mW, with a duration of 0.1 second. The laser was begun at the distal (corneal) end of the vessels and continued backward toward the limbus. The power was increased until occlusion of the vessels was visualized. The number of spots per session ranged from 30 to 501. Postoperatively, patients were treated with topical prednisolone acetate, 1%, drops 4 times a day and cyclopentolate hydrochloride, 1%, drops twice a day for 3 days.

Case 1

A 6-year-old boy was referred 1 month after corneal laceration repair and lensectomy following a penetrating pencil injury. Visual acuity with aphakic correction was 20/125 OS. The patient had a vascularized inferior corneal scar with traumatic corectopia (Figure 1). The patient underwent secondary intraocular lens implantation. One month postoperatively, the visual acuity was 20/80, with − 0.25 + 2.25 × 140°, and the corneal vascularization and scarring had progressed. The patient underwent 3 treatments with a yellow dye laser. Fourteen months after treatment, his visual acuity was 20/40, with − 3.75 + 2.0 × 155° (Figure 2).

Place holder to copy figure label and caption
Figure 1.

Patient 1 had vascularized inferior corneal scar.

Graphic Jump Location
Place holder to copy figure label and caption
Figure 2.

Patient 1 had a decreased central vascularity and opacity 1 month following laser treatment.

Graphic Jump Location
Case 2

A 16-year-old boy was struck in the left eye with a paintball, sustaining a corneoscleral laceration with iris prolapse that was surgically repaired. Postoperative ultrasonography revealed a retinal detachment, for which he underwent pars plana lensectomy and vitrectomy. His visual acuity 3 months following surgery was 20/200 with aphakic correction. He had a vascularized corneal scar. Three months following his third laser treatment, the central vascularization had resolved and his visual acuity was 20/20 with an aphakic contact lens.

Patient 3

A 15-year-old girl with hemifacial microsomia was observed since the age of 3 years. She had left-sided amblyopia, anisometropia, exotropia, ptosis with lagophthalmos, exposure keratopathy, and retinal and iris colobomas.Previous treatment included spectacles, patching, and penalization for amblyopia, strabismus surgery, and ocular lubrication. Her Snellen visual acuity maximized at 20/60 OS at the age of 6 years. She developed a dendritic corneal lesion at the age of 11 years, which was presumed to be herpetic. She was treated with acyclovir and topical corticosteroids. The active corneal lesion stabilized, but the patient continued to have a heavily vascularized corneal scar (Figure 3) and her visual acuity decreased to 20/200 because of the opacity and irregular astigmatism. She underwent 4 treatments with a yellow dye laser, with improvement in visual acuity to 20/70, with − 1.25 + 1.5 × 90°, and markedly decreased corneal vascularization (Figure 4).

Place holder to copy figure label and caption
Figure 3.

Patient 3 had a heavily vascularized corneal scar.

Graphic Jump Location
Place holder to copy figure label and caption
Figure 4.

Patient 3 had decreased vascularity and opacity 3 weeks following laser treatment.

Graphic Jump Location

Patients with corneal diseases may develop neovascularization of the cornea because of the growth of vessels across the limbus into the corneal stroma. This may result in opacification of the cornea, which may be exacerbated by leakage of lipid from the abnormal blood vessels.1Laser occlusion of the feeder vessels, initially with argon laser, has been used as a treatment for this condition.2,3The goals of treatment are to induce regression of neovascular vessels, resorb lipid, and improve visual function. Based on the absorption peak of hemoglobin in the yellow range, the yellow dye laser was demonstrated in animal studies to decrease neovascularization in animal models.4Baer and Foster5used the yellow dye laser to treat 23 patients with corneal neovascularization, with improvement in all patients except those with extensive neovascularization. Using a PubMed search, we were unable to find any previous reports of this treatment in pediatric patients.

The causes for the corneal neovascularization in our patients were traumatic corneal lacerations in patients 1 and 2 and a combination of chronic exposure keratopathy and presumed herpetic disease in patient 3. All patients demonstrated improvement in visual acuity. Possible complications of treatment include intrastromal hemorrhage, iris atrophy, and corneal thinning, none of which occurred in our patients. The laser is not adaptable for use under general anesthesia, so patients must be able to cooperate with applications at the slitlamp, including the use of a contact lens. The procedure is not painful but does require successive treatment sessions. Despite this, even our 6-year-old patient tolerated the treatment without difficulty.

The advantages of successful treatment of corneal neovascularization include improvement of visual acuity and appearance of the corneal scar. In addition, treatment may interrupt progressive opacification and lipid deposition and decrease the need for penetrating keratoplasty. In our 3 pediatric patients, the yellow dye laser safely and effectively decreased corneal neovascularization and improved visual function.

Correspondence:Dr Lueder, Departments of Ophthalmology and Visual Sciences and Pediatrics, St Louis Children's Hospital, Washington University School of Medicine, One Children's Place, Room 2s89, St Louis, MO 63110 (Lueder@vision.wustl.edu).

Financial Disclosure:None reported.

Previous Presentation:This study was presented at the American Association for Pediatric Ophthalmology and Strabismus Annual Meeting; April 12, 2007; Seattle, Washington.

Chang  JHGabison  EEKato  TAzar  DT Corneal neovascularization. Curr Opin Ophthalmol 2001;12 (4) 242- 249
PubMed
Cherry  PMHFaulkner  JDShaver  RPWise  JBWitter  SL Argon laser treatment of corneal neovascularization. Ann Ophthalmol 1973;5 (8) 911- 920
PubMed
Marsh  RJ Argon laser treatment of lipid keratopathy. Br J Ophthalmol 1988;72 (12) 900- 904
PubMed
Nirankari  VSDandona  LRodrigues  MM Laser photocoagulation of experimental corneal stromal vascularization: efficacy and histopathology. Ophthalmology 1993;100 (2) 111- 118
PubMed
Baer  JCFoster  S Corneal laser photocoagulation for treatment of neovascularization: efficacy of 577 nm yellow dye laser. Ophthalmology 1992;99 (2) 173- 179
PubMed

Figures

Place holder to copy figure label and caption
Figure 1.

Patient 1 had vascularized inferior corneal scar.

Graphic Jump Location
Place holder to copy figure label and caption
Figure 2.

Patient 1 had a decreased central vascularity and opacity 1 month following laser treatment.

Graphic Jump Location
Place holder to copy figure label and caption
Figure 3.

Patient 3 had a heavily vascularized corneal scar.

Graphic Jump Location
Place holder to copy figure label and caption
Figure 4.

Patient 3 had decreased vascularity and opacity 3 weeks following laser treatment.

Graphic Jump Location

Tables

References

Chang  JHGabison  EEKato  TAzar  DT Corneal neovascularization. Curr Opin Ophthalmol 2001;12 (4) 242- 249
PubMed
Cherry  PMHFaulkner  JDShaver  RPWise  JBWitter  SL Argon laser treatment of corneal neovascularization. Ann Ophthalmol 1973;5 (8) 911- 920
PubMed
Marsh  RJ Argon laser treatment of lipid keratopathy. Br J Ophthalmol 1988;72 (12) 900- 904
PubMed
Nirankari  VSDandona  LRodrigues  MM Laser photocoagulation of experimental corneal stromal vascularization: efficacy and histopathology. Ophthalmology 1993;100 (2) 111- 118
PubMed
Baer  JCFoster  S Corneal laser photocoagulation for treatment of neovascularization: efficacy of 577 nm yellow dye laser. Ophthalmology 1992;99 (2) 173- 179
PubMed

Correspondence

CME
Meets CME requirements for:
Browse CME for all U.S. States
Accreditation Information
The American Medical Association is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. The AMA designates this journal-based CME activity for a maximum of 1 AMA PRA Category 1 CreditTM per course. Physicians should claim only the credit commensurate with the extent of their participation in the activity. Physicians who complete the CME course and score at least 80% correct on the quiz are eligible for AMA PRA Category 1 CreditTM.
Note: You must get at least of the answers correct to pass this quiz.
You have not filled in all the answers to complete this quiz
The following questions were not answered:
Sorry, you have unsuccessfully completed this CME quiz with a score of
The following questions were not answered correctly:
Commitment to Change (optional):
Indicate what change(s) you will implement in your practice, if any, based on this CME course.
Your quiz results:
The filled radio buttons indicate your responses. The preferred responses are highlighted
For CME Course: A Proposed Model for Initial Assessment and Management of Acute Heart Failure Syndromes
Indicate what changes(s) you will implement in your practice, if any, based on this CME course.
NOTE:
Citing articles are presented as examples only. In non-demo SCM6 implementation, integration with CrossRef’s "Cited By" API will populate this tab (http://www.crossref.org/citedby.html).
Submit a Comment

Multimedia

Some tools below are only available to our subscribers or users with an online account.

Related Content

Customize your page view by dragging & repositioning the boxes below.

Articles Related By Topic
Related Topics